Recruiting Studies
Advanced SearchData: ClinicalTrials.gov · Source of record for eligibility and locations
Top Cities for Neuromyelitis Optica Clinical Trials
Neuromyelitis Optica clinical trials are recruiting across 20 cities. Here are the cities with the most active studies:
Neuromyelitis Optica Trial Phases
6 research organizations are sponsoring neuromyelitis optica trials.
About Neuromyelitis Optica
Neuromyelitis optica spectrum disorder (NMOSD) is a rare autoimmune disease that primarily attacks the optic nerves and spinal cord, causing vision loss and paralysis. It is distinct from multiple sclerosis and often involves aquaporin-4 antibodies. Treatment includes immunosuppressive therapies and biologics.
Clinical trials are advancing new treatments for neuromyelitis optica. Currently, 7 studies are recruiting a combined 363 participants across the United States. Research is being conducted by 6 organizations including Alexion Pharmaceuticals, Inc., Ad scientiam, Amgen and 3 others.
2026 Neuromyelitis Optica Research Landscape
As of July 2026, the neuromyelitis optica clinical trial landscape includes 7 actively recruiting studies across 20 cities in the United States. These studies are collectively seeking 363 participants, with an average enrollment target of 52 per study.
The research spans multiple phases of development: 2 studies are in NA, 1 study is in PHASE2, 1 study is in PHASE3. The presence of Phase 3 trials indicates that some neuromyelitis optica treatments are in late-stage testing and may be approaching regulatory review.
Research is being led by 6 different organizations, including Alexion Pharmaceuticals, Inc., Ad scientiam, Amgen, University of Texas Southwestern Medical Center, Icahn School of Medicine at Mount Sinai, and 1 others.
Geographically, neuromyelitis optica trials are most concentrated in Boston, Massachusetts (3 trials); Chapel Hill, North Carolina (2 trials); Dallas, Texas (2 trials); Washington D.C., District of Columbia (1 trial); Columbus, Ohio (1 trial) and 7 other cities.
Featured Neuromyelitis Optica Studies
Highlighted recruiting studies for neuromyelitis optica, selected by enrollment size and research scope.
Registry of Patients With AQP4+ NMOSD Treated With Alexion C5 Inhibitor Therapies
Long-term, multicenter, multinational, observational, registry of patients with AQP4+ NMOSD that is designed to collect data on clinical outcomes and safety in patients prescribed Alexion C5 inhibitor therapies (C5IT). The registry will also collect data on patient reported outcomes (PROs), quality of life (QoL), and targeted AQP4+ NMOSD therapies used to provide evidence on the real-world impact ...
Performance and Safety of a Digital Tool for Unsupervised Self-assessment of NMOSD
NMOSDCopilot is a digital tool developed for the self-assessment of Neuromyelitis Optica Spectrum Disorder symptoms that impact patients' functioning and quality of life. It has been co-designed with the help of patient advocacy groups, NMOSD patients and medical experts. It includes a smartphone-based application for patients, connected to a web portal developed for healthcare professionals (HCSP...
Observational Safety Study in Women With Neuromyelitis Optica Spectrum Disorder (NMOSD) Exposed to UPLIZNA® During Pregnancy
This is an observational study to monitor female participants exposed to UPLIZNA during pregnancy. This study requires voluntary reporting of pregnancies in female participants with NMOSD exposed to UPLIZNA during pregnancy or within 6 months preceding conception. Pregnancy-related data, potential confounding factors and information related to pregnancy outcome will be collected. The schedule of o...
Frequently Asked Questions About Neuromyelitis Optica Clinical Trials
Are there neuromyelitis optica clinical trials near me?
Yes, there are 7 neuromyelitis optica clinical trials currently recruiting across 20+ cities in the United States, including Boston, Massachusetts; Chapel Hill, North Carolina; Dallas, Texas. Browse the studies above to find one at a location convenient for you.
How do I join a neuromyelitis optica clinical trial?
To join a neuromyelitis optica clinical trial: 1) Browse the available studies on this page, 2) Click on a study that interests you, 3) Check the study locations to find a site near you, 4) Review the eligibility criteria, and 5) Contact the study site or complete the eligibility form. The process is free and you can withdraw at any time.
Are neuromyelitis optica clinical trials free?
Yes, participation in neuromyelitis optica clinical trials is free. Study-related treatments, medical tests, and doctor visits are provided at no cost to participants. Many studies also offer compensation for your time and travel expenses.
What types of neuromyelitis optica treatments are being studied?
Current neuromyelitis optica clinical trials are testing a range of approaches across NA (2 studies), PHASE2 (1 study), PHASE3 (1 study). These include new drugs, combination therapies, medical devices, and other interventions sponsored by 6 research organizations.
Is it safe to participate in neuromyelitis optica clinical trials?
Clinical trials are carefully regulated by the FDA and institutional review boards (IRBs). All trials must follow strict safety protocols, and participants receive close medical monitoring throughout the study. You can withdraw from a trial at any time without penalty.
Data updated July 18, 2026 from ClinicalTrials.gov
About This Data
Data: ClinicalTrials.gov · Source of record for eligibility and locations
Clinical trial information on this page is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health (NIH) and National Library of Medicine (NLM). Study data is refreshed every hour to ensure accuracy.
Medical Disclaimer: The information provided on this page is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before making decisions about clinical trial participation or changes to your treatment plan.
Page reviewed by the HelloStudys Research Team · Last updated July 18, 2026 · Data from ClinicalTrials.gov